Mammalian cells present the main expression platforms for production of recombinant therapeutic proteins. To cope with the increased demand for these therapeutics, more productive manufacturing processes have been developed using high-density cultures and enriched feeds/media. This has dramatically increased the productivity of mammalian cells in culture but this is accompanied by an increased production and accumulation of lactate in cultures, with the pattern of phasic production and consumption of lactate associated with the cell productivity in culture. Although primarily defined as a waste product, it is clear that lactate metabolism presents a control node for determination of process control and effectiveness of manufacturing strategies. This review focuses on recent understanding of the phasic nature of lactate metabolism, the impact of culture environment (media, feeds) on lactate metabolism, the link between lactate metabolic status and cell status and the culture/metabolic engineering approaches that have been applied to generate the lactate metabolic phenotype associated with a highly productive manufacturing process
Introduction
In the last 30 years, major improvements in final product titres and viable cell density have been achieved in mammalian cell-based cultures with the upstream process optimisation (i.e., culture operation and tailor-made medium/feeds) [1] . Associated with the drive towards enhanced biomass, metabolic processing of enriched feeds has led to the accumulation of metabolic "waste" products that have consequences on the productivity and quality of therapeutic recombinant (r-) protein products. Great attention has been directed on production and accumulation of lactate in culture as a waste product but recent attention has illustrated that other metabolites can accumulate and become growth limitating to Chinese Hamster Ovary (CHO) cells [2, 3] . A recent review has focused on the molecular mechanisms through which lactate metabolism can be regulated [4  ]. Here we direct attention to the manufacturing perspective and how lactate metabolism, and its potential as an indicator of process status, offers a model for understanding how it may prove possible to rationalise manufacture optimisation.
In CHO cell systems, lactate concentrations above 20 mM diminish r-protein yield, whilst concentrations exceeding 40 mM severely impair growth [5, 6] . The implementation of large-scale fedbatch or perfusion operation using CHO cells has driven lactate accumulation above 80 mM [7,8  ,9] and maintenance of the optimal culture pH in bioreactors necessitates addition of high amounts of alkali. Addition of alkali, by increased osmolality, can inhibit cell growth and, additionally, lead to lower r-protein production [10] . A multivariate analysis of Genentech's manufacturing data highlighted lactate metabolism as a key parameter in determining final productivity of a process [11] . Similar conclusions have been generated by two other independent analyses with data from different manufacturing processes [12, 13] . Hence, from a bioprocess perspective, restricting lactate production would aid the development of robust and productive therapeutic r-protein production and, at process and metabolic engineering levels, several strategies have been applied to reduce lactate formation and redirect lactate towards consumption ( Figure 1) .
Changing lactate metabolism through modification of culture environment
Recent studies exploring the carbon flux distribution in industrially-relevant mammalian cell lines
showed that that around 60-80% of glucose and 16-25% of glutamine are converted into lactate during the exponential phase [12, 13, 14, 15] . The metabolism status of glucose and glutamine are a key determinant in the switch from lactate production to consumption, an event widely reported to occur when glucose or glutamine availability is limited [5, 16, 17] . A survey of several manufacturing runs at Genentech indicated that lactate consumption was a prominent factor in determining the productivity of r-proteins in production-scale cultures [11] . The profile of lactate metabolism is not solely down to glucose availability as lactate consumption has been reported even when there is appreciable amount of glucose in the culture medium [16] [17] [18] . Two independent studies observed that glutamine availability modulates lactate fate (either production or consumption) at the end of culture [16, 18] and a strong positive correlation was observed between the lactate and glutamine metabolism (after the metabolic shift) in CHO cells [18] . As the pattern of lactate metabolism is closely linked to glucose and glutamine metabolism, many of the strategies to develop a decreased lactate production phenotype are focused on the control of these two carbon sources.
Many different sugars, such as galactose, fructose, mannose or maltose, have been proposed as substitutes to glucose, offering the advantage of slower consumption than glucose in culture, leading to less lactate production. Substitution of glucose by galactose, for example, produced significantly less lactate but decreased specific cell growth rate and peak viable cell density [19] . To enhance cell biomass, a biphasic culture strategy (alternating the consumption of glucose and galactose) has been proposed in CHO cell batch and fed-batch cultures [20, 21] . Using this strategy, high cell densities have been achieved with significantly decreased (up 66%) lactate accumulation and improved galactosylation in fed-batch cultures [20] [21] [22] . Aternatives to glutamine (glutamate, pyruvate, TCA cycle intermediaries and dipeptides) have also been developed. Initially aimed at decreasing ammonia accumulation, these approaches have also impacted on the lactate formation. The use of glutamate, pyruvate or dipeptides such as L-alanyl-L-glutamine (commercially available as Changing lactate metabolism through modification of process Linear correlations have been observed between specific lactate production rate and the setpoints for pH and temperature in batch cultures [35] . Temperature decrease slows cell metabolism, with a decreased consumption of glucose and glutamine and production of lactate both in batch and fedbatch cultures [36, 37] . In some studies, decreased culture temperature leads to lactate consumption [17, 18] , in a cell line-dependent manner. Decreased culture pH, via changes to the activity of glycolytic enzymes and membrane potential, is associated with decreased rates of specific glucose consumption and lactate production [38] . Several studies have shown that the metabolic switch from lactate production to lactate consumption in mammalian cells is dependent on the culture pH setpoint [39, 40] . However, as both strategies influence cell growth, r-protein productivity and glycosylation adversely [41, 42] , the lactate metabolism are optimized on a case-by-case basis in biphasic cultures where these parameters are first controlled to setpoints which favor extensive cell proliferation prior to shifts to setpoints where lactate metabolism is modified [40] .
Changing lactate metabolism by metabolic engineering
Regulating the expression of GLUT transporters in combination with the use of alternative carbon sources have been proposed to improve culture performance of recombinant mammalian cells. The most successful case has been the overexpression of the GLUT5 fructose-specific transporter with fructose as main carbon source in culture medium. This strategy led to a dramatic decrease in lactate production rates and an increase in viable cell density compared to glucose-based cultures, in human myeloma derived and CHO cell lines [43, 44] . However, the consequence of overexpression of GLUT5
for lactate metabolism by recombinant cell lines depends to a large extent on the regulation of expression of the glut5 gene. To illustrate this, Le et al. [45] proposed a biphasic culture strategy using a GLUT5 dynamic expression system in concert with cell growth. This strategy enabled cells to consume fructose according to cellular needs rather than in excess as typically seen in culture, thus
driving better cell growth, higher product titre and lower lactate production. Coversely, Wilkens and Gerdtzen using a constitutive GLUT5-overexpressing CHO cell line in a conventional batch with fructose as the main carbon source reported increased cell growth and IgG production, but similar lactate production compared to glucose-based cultures [46] .
Prevention of activity of lactate dehydrogenase (LDH-A) appears a direct strategy to decrease lactate production. Elimination of LDH-A by gene knock-out is lethal for mammalian cells [47  ].
Consequently, efforts have focused on knocking down (rather than knocking-out) LDH-A activity.
Approaches, such as homologous recombination [48] , antisense mRNA expression technology [49, 50] or small interfering RNA (siRNA) [51] , have been shown to decrease LDH-A activity to different 
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Overexpression of malate dehydrogenase II (MDH II) has been also proposed as a strategy to overcome a TCA cycle bottleneck and improve energy metabolism in CHO cells [46, 59] . These two independent reports developed MDH II-overexpressing CHO cell lines with significantly decreased lactate production and decreased the NAD+/NADH ratio but with contradictory results on the value to MDH II as a target to enhance cell growth.
Concluding comments and future perspectives
The increased understanding of lactate metabolism has made it possible to develop strategies that decrease lactate accumulation in cultures. Lactate produced during the culture processes of mammalian cells is regarded as a waste product that is detrimental to efficient cell performance and development of the manufacturing platform. Yet this view is arguably too simplistic. Under specific metabolic (or culture phase) conditions cells can use lactate to provide part of the metabolic input that is associated with prolongment of culture or enhanced production of recombinant proteins. From a manufacturing perspective, lactate production (associated with rapid cell growth during exponential culture phase) is valuable if subsequent consumption of lactate can be built into the cell culture process. Combination of process and metabolic engineering offers a promising approach to generate an effective balance of a limited early lactate production and subsequent lactate consumption. For instance, the overexpression of PYC2 combined with a rational feed design has proven to be a successful approach for the development of high-titre fed-batch cultures with a consistently advantageous profile of lactate metabolism in different industrially-relevant mammalian cell lines [56] [57] [58] . Selection of clones with a desirable lactate metabolic profile (low-producing/high-consuming phenotype) offers a route to an better overall metabolic phenotype. However, the lactate-consuming phenotypehas been reported to be lost due to unknown factors for certain clones, even in validated cGMP processes making commercial products [11] , and such a selection criterion may increase the chances of discarding good production clones. 
